SCHEMBL30406469

SCHEMBL30406469

COc1c(Br)ccc2[nH]c(C#N)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
HSD17B10 Q99714 2/20 0.36
TSHR P16473 1/20 0.36
GFER P55789 1/20 0.36
HTR1A P08908 2/20 0.35
DRD2 P14416 2/20 0.35
TUBB4A P04350 7/20 0.35
TUBB P07437 7/20 0.35
TUBA3C P0DPH7 7/20 0.35
TUBA1B P68363 7/20 0.35
TUBA4A P68366 7/20 0.35
TUBB4B P68371 7/20 0.35
TUBB3 Q13509 7/20 0.35
TUBB2A Q13885 7/20 0.35
TUBB8 Q3ZCM7 7/20 0.35
TUBA3E Q6PEY2 7/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25421574 1.00 MEN1 (0.36) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL16031335 0.83 STING1 (0.38) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL16156325 0.81 HTR1A (0.36) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL16149538 0.79 HTR1A (0.37) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL25421875 0.78 ALDH1A1 (0.38) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL30405780 0.78 ALDH1A1 (0.38) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL17522629 0.73 PTGDR (0.38) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL993313 0.71 AHR (0.41) ALDH1A1MAPTHTR1ADRD2ADRB2
SCHEMBL30295644 0.71 AHR (0.41) ALDH1A1MAPTHTR1ADRD2ADRB2
SCHEMBL20504885 0.71 ADRB2 (0.52) MEN1KMT2AKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-4444300-A2 INHIBITORS OF MENIN-MLL INTERACTION Bala Therapeutics, Inc. (US) 2024-10-16 EP disclosed
CN-118647378-A Inhibitors of Mei Nen protein interaction with MLL 巴拉疗法公司 2024-09-13 CN disclosed
WO-2023107696-A2 INHIBITORS OF MENIN-MLL INTERACTION BALA THERAPEUTICS, INC. (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163061-A1 INHIBITORS OF MENIN-MLL INTERACTION MLLT1, MEN1, BMI1 MEN1 2/4885KMT2A 8/4885KDM4E 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.